1. GSK allies with Innovax for COVID-19 vaccine R&D project— Zentalis Pharma raises $165M in IPO — Drug discovery in the age of coronavirus — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Libtayo resignations

Discussion in 'Regeneron' started by anonymous, Sep 23, 2019 at 12:55 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Don't forget Chicago under Regeneron. More to come!!!
     

  2. anonymous

    anonymous Guest

    Going to be extremely difficult to backfill those slots with anyone who has oncology experience or a strong specialty track record. Too many better opps out there.
     
  3. anonymous

    anonymous Guest

    Curious why so many reps and the manager have left. Anyone willing to share what the salary range is? Are most reps here new to oncology?
     
  4. anonymous

    anonymous Guest

    Leadership
     
  5. anonymous

    anonymous Guest

    Yes- the lack of
     
  6. anonymous

    anonymous Guest

    Metoovamab $48m in Q3 sales. Merck must be trembling in their boots.
     
  7. anonymous

    anonymous Guest

    3 more resign
     
  8. anonymous

    anonymous Guest

    MA gone!!!! No way
     
  9. anonymous

    anonymous Guest


    What geography?
     
  10. anonymous

    anonymous Guest

    Cleveland Detroit and Minneapolis. Gone.
    Who is MA??
     
  11. anonymous

    anonymous Guest

    LA most recent to quit.
     
  12. anonymous

    anonymous Guest

    Why so many resignations?
     
  13. anonymous

    anonymous Guest

    Weak product and weaker leadership. Handwriting is on the wall, layoffs and / or re-assignments on the not too distant horizon.
     
  14. anonymous

    anonymous Guest


    Then WHY are they expanding by 15 reps and two RM's? Oh wait................
     
  15. anonymous

    anonymous Guest

    Corporate always believes more bodies equal more sales. Never considers access limitations in oncology. Nearly every company makes this mistake. This is how BMS Merck AZ all end up with 8 reps in the same territory. It is dumb.
     
  16. anonymous

    anonymous Guest

    Hire to fire...
     
  17. anonymous

    anonymous Guest

    Because they are inexperienced and arrogant fools.
     
  18. anonymous

    anonymous Guest

    Arrogance is the Regeneron Way
     
  19. anonymous

    anonymous Guest

    This place is such a turd farm.
     
  20. anonymous

    anonymous Guest

    What’s the truth? Sounds like the pay is good both salary and bonus? They got people from Merck etc also so? Sounds pretty good to me, but like all pharma it is the manager who makes or breaks you most of the time. How are RDs? Honest answers please I’m seriously considering.